Toripalimab, an emerging cancer therapy developed by Zhangjiang’s Junshi Biosciences, is applied in treatment at the Beijing Cancer Hospital for the first time on Feb 26. [Photo/pdtimes.com.cn]

Shanghai has been continuously introducing relevant policies in the pharmaceutical industry in recent years, creating many opportunities for its biomedical innovation enterprises.

The in-depth promotion of some pilot programs, the marketing authorization holder (MAH) system and the medical device registration system, for example, have accelerated the industrialization of homegrown innovative drugs, and helped the local enterprises seize market opportunities.

The Zhangjiang National Innovation Demonstration Zone, also known as Zhangjiang Pharma Valley, is a manufacturing base of biological medicine for Shanghai and an industry leader in China.

According to Lou Qi, general manager of Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co Ltd, the enterprises in Zhangjiang cover many forward-looking fields, including tumor immunotherapy, cell therapy, gene therapy and next-generation sequencing.